Efficacy and Safety of JAK Inhibitor Combined with IL-17A Inhibitor for Eczematous Psoriasis: A Prospective, Single-Center, Randomized Controlled, Open-Label Trial

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 961dd0f2b4fc8e60062562c76ec95ac5308ddea4
First added on: Jan 17, 2026